The comparison of efficacy and safety between cadonilimab (PD-1/CTLA-4) and anti-PD-1 inhibitors in patients with recurrent or metastatic cervical cancer: a retrospective real-world study
Cadonilimab improved survival in R/M CC patients with previous anti-PD-1 treatment failure, achieving higher ORR in patients with negative PD-L1 expression compared to ati-PD-1 inhibitors. However, this benefit was associated with a notable increase in irAEs.
Authors
- Jia‐Xin Yin (ORCID: https://orcid.org/0000-0003-2661-4206)
- Jundong Li (ORCID: https://orcid.org/0000-0002-1878-817X)
- Shanyang He (ORCID: https://orcid.org/0000-0002-3793-569X)
- Baoyue Pan (ORCID: https://orcid.org/0000-0001-5922-7136)
- Qidan Huang (ORCID: https://orcid.org/0000-0002-5158-1517)
- Min Zheng (ORCID: https://orcid.org/0000-0002-0329-9680)
- He Huang (ORCID: https://orcid.org/0000-0003-3008-4869)
- Siyu Chen (ORCID: https://orcid.org/0000-0002-3809-1062)
- Shijie Xu (ORCID: https://orcid.org/0000-0003-1840-8592)
- Ting Wan (ORCID: https://orcid.org/0000-0002-6229-4441)
Institutions
- Sun Yat-sen University (CN)
- Guangdong Academy of Medical Sciences (CN)
- Sun Yat-sen University Cancer Center (CN)
- Guangdong Provincial People's Hospital (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-06-02
- DOI
- https://doi.org/10.3389/fimmu.2025.1582299
- Citations
- 5
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 5.23
Funders
- Bethune Charitable Foundation
- Wu Jieping Medical Foundation
- Key Technologies Research and Development Program of Guangzhou
- Basic and Applied Basic Research Foundation of Guangdong Province